These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27064574)

  • 1. Heterogeneity of KRAS Mutation Status in Rectal Cancer.
    Jo P; König A; Schirmer M; Kitz J; Conradi LC; Azizian A; Bernhardt M; Wolff HA; Grade M; Ghadimi M; Ströbel P; Schildhaus HU; Gaedcke J
    PLoS One; 2016; 11(4):e0153278. PubMed ID: 27064574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
    Yoon G; Lee H; Kim JH; Hur K; Seo AN
    Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer.
    Jo P; Bernhardt M; Nietert M; König A; Azizian A; Schirmer MA; Grade M; Kitz J; Reuter-Jessen K; Ghadimi M; Ströbel P; Schildhaus HU; Gaedcke J
    PLoS One; 2020; 15(10):e0239806. PubMed ID: 33002027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
    Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
    Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics.
    Krajnović M; Marković B; Knežević-Ušaj S; Nikolić I; Stanojević M; Nikolić V; Šiljić M; Jovanović Ćupić S; Dimitrijević B
    Pathol Res Pract; 2016 Jul; 212(7):598-603. PubMed ID: 27184911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment.
    Boissière-Michot F; Lopez-Crapez E; Frugier H; Berthe ML; Ho-Pun-Cheung A; Assenat E; Maudelonde T; Lamy PJ; Bibeau F
    Mod Pathol; 2012 May; 25(5):731-9. PubMed ID: 22282307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
    Duldulao MP; Lee W; Nelson RA; Li W; Chen Z; Kim J; Garcia-Aguilar J
    Ann Surg Oncol; 2013 Jul; 20(7):2166-71. PubMed ID: 23456389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
    Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
    Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical influence of cancer stem cells on residual disease after preoperative chemoradiotherapy for rectal cancer.
    Yoon G; Kim SM; Kim HJ; Seo AN
    Tumour Biol; 2016 Mar; 37(3):3571-80. PubMed ID: 26456957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?
    Ondrejka SL; Schaeffer DF; Jakubowski MA; Owen DA; Bronner MP
    Am J Surg Pathol; 2011 Sep; 35(9):1327-30. PubMed ID: 21836482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
    Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
    PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
    Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.
    Clancy C; Burke JP; Coffey JC
    Surg Oncol; 2013 Jun; 22(2):105-11. PubMed ID: 23473635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
    Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome landscapes of rectal cancer before and after preoperative chemoradiotherapy.
    Yang J; Lin Y; Huang Y; Jin J; Zou S; Zhang X; Li H; Feng T; Chen J; Zuo Z; Zheng J; Li Y; Gao G; Wu C; Tan W; Lin D
    Theranostics; 2019; 9(23):6856-6866. PubMed ID: 31660073
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Sideris M; Moorhead J; Diaz-Cano S; Haji A; Papagrigoriadis S
    Anticancer Res; 2017 Mar; 37(3):1349-1357. PubMed ID: 28314302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery.
    Peng J; Lin J; Qiu M; Zhao Y; Deng Y; Shao J; Ding P; Zhang H; Wan D; Lu Z; Pan Z
    Tumour Biol; 2017 Jul; 39(7):1010428317709638. PubMed ID: 28671043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery.
    Lee JW; Lee JH; Shim BY; Kim SH; Chung MJ; Kye BH; Kim HJ; Cho HM; Jang HS
    Medicine (Baltimore); 2015 Aug; 94(31):e1284. PubMed ID: 26252300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
    Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.